First Quarter of Fiscal Year 2025 – Consolidated Earnings Highlights

Revenue of $292.3 million
Net loss of $44.5 million
Adjusted EBITDA* of $(1.7) million

Fiscal Year 2025 Guidance Ranges:

Revenue expected in a range of $1.425 billion to $1.525 billion
Net income (loss) expected in a range of $(59) million to $3 million
Adjusted EBITDA* expected in a range of $100 million to $130 million

First Quarter Fiscal Year 2025 – Segment Highlights

Senior

Revenue of $92.9 million
Adjusted EBITDA* of $7.7 million
Approved Medicare Advantage policies of 91,680

Healthcare Services

Revenue of $155.7 million
Adjusted EBITDA* of $4.9 million
86,521 SelectRx members

Life

Revenue of $39.3 million
Adjusted EBITDA* of $6.0 million

SelectQuote, Inc. (NYSE:SLQT) reported consolidated revenue for the first quarter of fiscal year 2025 of $292.3 million compared to consolidated revenue for the first quarter of fiscal year 2024 of $232.7 million. Consolidated net loss for the first quarter of fiscal year 2025 was $44.5 million compared to consolidated net loss for the first quarter of fiscal year 2024 of $31.1 million. Finally, consolidated Adjusted EBITDA* for the first quarter of fiscal year 2025 was $(1.7) million compared to consolidated Adjusted EBITDA* for the first quarter of fiscal year 2024 of $(11.4) million.

SelectQuote Chief Executive Officer, Tim Danker, remarked, "SelectQuote opened our fiscal 2025 with a strong quarter and our holistic approach to healthcare connectivity between Americans in need of care, and the insurers and caregivers that provide it, has never been more valuable. As reported in the market, benefit coverage for Medicare Advantage plans shifted significantly this season, and we are pleased to say that both seniors and insurance carriers have increasingly turned to SelectQuote's agent-led, true-choice platform to ensure individual care needs are met with the best plan available. When our customers and carrier partners benefit, so do our performance metrics and shareholders, and we proud of this alignment."

Mr. Danker continued, "This quarter was also a success for our broadening Healthcare Services platform led by SelectRx. Our bespoke prescription drug service now has over 86 thousand members, which represents growth of over 64% compared to a year ago. Separately, SelectQuote recently announced our initial receivable securitization, which was a critical first step in our ongoing strategy to improve our capital flexibility."

"We look forward to sharing our AEP results next quarter and are excited by the value our differentiated model continues to provide to a large and growing population of American seniors," Mr. Danker concluded.

* See "Non-GAAP Financial Measures" below.

Segment Results

We currently have three reportable segments: 1) Senior, 2) Healthcare Services and 3) Life. The performance measures of the segments include total revenue and Adjusted EBITDA.* Costs of commissions and other services revenue, cost of goods sold-pharmacy revenue, marketing and advertising, selling, general, and administrative, and technical development operating expenses that are directly attributable to a segment are reported within the applicable segment. Indirect costs of revenue, marketing and advertising, selling, general, and administrative, and technical development operating expenses are allocated to each segment based on varying metrics such as headcount. Adjusted EBITDA is our segment profit measure to evaluate the operating performance of our business. We define Adjusted EBITDA as net loss plus: (i) interest expense, net; (ii) expense (benefit) for income taxes; (iii) depreciation and amortization; (iv) share-based compensation; (v) goodwill, long-lived asset, and intangible assets impairments; (vi) transaction costs; (vii) loss on disposal of property, equipment and software, net; and (viii) other non-recurring expenses and income. Adjusted EBITDA Margin is calculated as Adjusted EBITDA divided by revenue.

Senior

Financial Results

The following table provides the financial results for the Senior segment for the periods presented:

(in thousands)		1Q 2025			1Q 2024		% Change
Revenue	$	92,908		$	89,918		3	%
Adjusted EBITDA*		7,724			(1,335	)	679	%
Adjusted EBITDA Margin*		8	%		(1	)%

Operating Metrics

Submitted Policies

Submitted policies are counted when an individual completes an application with our licensed agent and provides authorization to the agent to submit the application to the insurance carrier partner. The applicant may have additional actions to take before the application will be reviewed by the insurance carrier.

The following table shows the number of submitted policies for the periods presented:

	1Q 2025	1Q 2024	% Change
Medicare Advantage	102,281	104,532	(2	)%
All other ⁽¹⁾	16,256	14,920	9	%
Total	118,537	119,452	(1	)%

(1) Represents the submitted policies for medicare supplement, dental, vision and hearing, prescription drug plan and other.

Approved Policies

Approved policies represents the number of submitted policies that were approved by our insurance carrier partners for the identified product during the indicated period. Not all approved policies will go in force.

* See "Non-GAAP Financial Measures" below.

The following table shows the number of approved policies for the periods presented:

	1Q 2025	1Q 2024	% Change
Medicare Advantage	91,680	97,681	(6	)%
All other ⁽¹⁾	12,979	12,195	6	%
Total	104,659	109,876	(5	)%

(1) Represents the approved policies for medicare supplement, dental, vision and hearing, prescription drug plan and other.

Lifetime Value of Commissions per Approved Policy

Lifetime value of commissions per approved policy represents commissions estimated to be collected over the estimated life of an approved policy based on multiple factors, including but not limited to, contracted commission rates, carrier mix and expected policy persistency with applied constraints. The lifetime value of commissions per approved policy is equal to the sum of the commission revenue due upon the initial sale of a policy, and when applicable, an estimate of future renewal commissions.

The following table shows the lifetime value of commissions per approved policy for the periods presented:

(dollars per policy):		1Q 2025		1Q 2024	% Change
Medicare Advantage	$	812	$	761	7	%
All other ⁽¹⁾		165		164	—	%

(1) Represents the weighted average LTV per approved policy.

Healthcare Services

Financial Results

The following table provides the financial results for the Healthcare Services segment for the periods presented:

(in thousands)		1Q 2025			1Q 2024		% Change
Revenue	$	155,739		$	97,368		60	%
Adjusted EBITDA*		4,878			2,322		110	%
Adjusted EBITDA Margin*		3	%		2	%

Operating Metrics

Members

The total number of SelectRx members represents the amount of active customers to which an order has been shipped and the prescriptions per day represents the total average prescriptions shipped per business day. These two metrics are the primary drivers of revenue for Healthcare Services.

The following table shows the total number of SelectRx members as of the periods presented:

		September 30, 2024		September 30, 2023
Total SelectRx Members		86,521		52,750

The total number of SelectRx members increased by 64% as of September 30, 2024, compared to September 30, 2023, due to our continued operating strategy to grow SelectRx.

* See "Non-GAAP Financial Measures" below.

The following table shows the average prescriptions shipped per day for the periods presented:

		September 30, 2024		September 30, 2023
Prescriptions Per Day		24,998		15,479

Combined Senior and Healthcare Services - Consumer Per Unit Economics

The opportunity to leverage our existing database and distribution model to improve access to healthcare services for our consumers has created a need for us to review our key metrics related to our per unit economics. As we think about the revenue and expenses for Healthcare Services, we note that they are derived from the marketing acquisition costs associated with the sale of an MA or MS policy, some of which costs are allocated directly to Healthcare Services, and therefore determined that our per unit economics measure should include components from both Senior and Healthcare Services. See details of revenue and expense items included in the calculation below.

Combined Senior and Healthcare Services consumer per unit economics represents total MA and MS commissions; other product commissions; other revenues, including revenues from Healthcare Services; and operating expenses associated with Senior and Healthcare Services, each shown per number of approved MA and MS policies over a given time period. Management assesses the business on a per-unit basis to help ensure that the revenue opportunity associated with a successful policy sale is attractive relative to the marketing acquisition cost. Because not all acquired leads result in a successful policy sale, all per-policy metrics are based on approved policies, which is the measure that triggers revenue recognition.

The MA and MS commission per MA/MS policy represents the LTV for policies sold in the period. Other commission per MA/MS policy represents the LTV for other products sold in the period, including DVH prescription drug plan, and other products, which management views as additional commission revenue on our agents' core function of MA/MS policy sales. Pharmacy revenue per MA/MS policy represents revenue from SelectRx, and other revenue per MA/MS policy represents revenue from Population Health, production bonuses, marketing development funds, lead generation revenue, and adjustments from the Company's reassessment of its cohorts' transaction prices. Total operating expenses per MA/MS policy represents all of the operating expenses within Senior and Healthcare Services. The revenue to customer acquisition cost ("CAC") multiple represents total revenue as a multiple of total marketing acquisition cost, which represents the direct costs of acquiring leads. These costs are included in marketing and advertising expense within the total operating expenses per MA/MS policy.

The following table shows combined Senior and Healthcare Services consumer per unit economics for the periods presented. Based on the seasonality of Senior and the fluctuations between quarters, we believe that the most relevant view of per unit economics is on a rolling 12-month basis. All per MA/MS policy metrics below are based on the sum of approved MA/MS policies, as both products have similar commission profiles.

	Twelve Months Ended September 30,
(dollars per approved policy):		2025			2024
MA and MS approved policies		621,040			594,554
MA and MS commission per MA / MS policy	$	919		$	872
Other commission per MA/MS policy		12			13
Pharmacy revenue per MA/MS policy		842			493
Other revenue per MA/MS policy		152			151
Total revenue per MA / MS policy		1,925			1,529
Total operating expenses per MA / MS policy		(1,626	)		(1,278	)
Adjusted EBITDA per MA/MS policy *	$	299		$	251
Adjusted EBITDA Margin per MA/MS policy *		16	%		16	%
Revenue / CAC multiple	4.6X			4.3X

Total revenue per MA/MS policy increased 26% for the twelve months ended September 30, 2024, compared to the twelve months ended September 30, 2023, primarily due to the increase in pharmacy revenue. Total operating expenses per MA/MS policy increased 27% for the twelve months ended September 30, 2024, compared to the twelve months ended September 30, 2023, driven by an increase in cost of goods sold-pharmacy revenue for Healthcare Services due to the growth of the business.

Life

Financial Results

The following table provides the financial results for the Life segment for the periods presented:

(in thousands)		1Q 2025			1Q 2024		% Change
Revenue	$	39,290		$	37,803		4	%
Adjusted EBITDA*		5,960			5,240		14	%
Adjusted EBITDA Margin*		15	%		14	%

Operating Metrics

Life premium represents the total premium value for all policies that were approved by the relevant insurance carrier partner and for which the policy document was sent to the policyholder and payment information was received by the relevant insurance carrier partner during the indicated period. Because our commissions are earned based on a percentage of total premium, total premium volume for a given period is the key driver of revenue for our Life segment.

The following table shows term and final expense premiums for the periods presented:

(in thousands)		1Q 2025		1Q 2024	% Change
Term Premiums	$	15,218	$	18,190	(16	)%
Final Expense Premiums		24,473		19,699	24	%
Total	$	39,691	$	37,889	5	%

* See "Non-GAAP Financial Measures" below.

Earnings Conference Call

SelectQuote, Inc. will host a conference call with the investment community on November 4, 2024, beginning at 8:30 a.m. ET. To register for this conference call, please use this link: https://registrations.events/direct/Q4I1559258472. After registering, a confirmation will be sent via email, including dial-in details and unique conference call codes for entry. Registration is open through the live call, but to ensure you are connected for the full call we suggest registering at least 10 minutes before the start of the call. The event will also be webcasted live via our investor relations website https://ir.selectquote.com/investor-home/default.aspx.

Non-GAAP Financial Measures

This release includes certain non-GAAP financial measures intended to supplement, not substitute for, comparable GAAP measures. To supplement our financial statements presented in accordance with GAAP and to provide investors with additional information regarding our GAAP financial results, we have presented in this release Adjusted EBITDA and Adjusted EBITDA Margin, which are non-GAAP financial measures. These non-GAAP financial measures are not based on any standardized methodology prescribed by GAAP and are not necessarily comparable to similarly titled measures presented by other companies. We define Adjusted EBITDA as net income (loss) before interest expense, income tax expense (benefit), depreciation and amortization, and certain add-backs for non-cash or non-recurring expenses, including restructuring and share-based compensation expenses. The most directly comparable GAAP measure is net income (loss). We define Adjusted EBITDA Margin as Adjusted EBITDA divided by revenue. The most directly comparable GAAP measure is net income margin. We monitor and have presented in this release Adjusted EBITDA and Adjusted EBITDA Margin because they are key measures used by our management and Board of Directors to understand and evaluate our operating performance, to establish budgets, and to develop operational goals for managing our business. In particular, we believe that excluding the impact of these expenses in calculating Adjusted EBITDA can provide a useful measure for period-to-period comparisons of our core operating performance. We believe that these non-GAAP financial measures help identify underlying trends in our business that could otherwise be masked by the effect of the expenses that we exclude in the calculations of these non-GAAP financial measures. Accordingly, we believe that these financial measures provide useful information to investors and others in understanding and evaluating our operating results, enhancing the overall understanding of our past performance and future prospects. Reconciliations of net income (loss) to Adjusted EBITDA are presented below beginning on page 13.

Forward Looking Statements

This release contains forward-looking statements. These forward-looking statements reflect our current views with respect to, among other things, future events and our financial performance. These statements are often, but not always, made through the use of words or phrases such as "may," "should," "could," "predict," "potential," "believe," "will likely result," "expect," "continue," "will," "anticipate," "seek," "estimate," "intend," "plan," "projection," "would" and "outlook," or the negative version of those words or other comparable words or phrases of a future or forward-looking nature. These forward-looking statements are not historical facts, and are based on current expectations, estimates and projections about our industry, management's beliefs and certain assumptions made by management, many of which, by their nature, are inherently uncertain and beyond our control. Accordingly, we caution you that any such forward-looking statements are not guarantees of future performance and are subject to risks, assumptions and uncertainties that are difficult to predict. Although we believe that the expectations reflected in these forward-looking statements are reasonable as of the date made, actual results may prove to be materially different from the results expressed or implied by the forward-looking statements.

There are or will be important factors that could cause our actual results to differ materially from those indicated in these forward-looking statements, including, but not limited to, the following: impacts of the COVID-19 pandemic and any other significant public health events; our reliance on a limited number of insurance carrier partners and any potential termination of those relationships or failure to develop new relationships; existing and future laws and regulations affecting the health insurance market; changes in health insurance products offered by our insurance carrier partners and the health insurance market generally; insurance carriers offering products and services directly to consumers; changes to commissions paid by insurance carriers and underwriting practices; competition with brokers, exclusively online brokers and carriers who opt to sell policies directly to consumers; competition from government-run health insurance exchanges; developments in the U.S. health insurance system; our dependence on revenue from carriers in our senior segment and downturns in the senior health as well as life, automotive and home insurance industries; our ability to develop new offerings and penetrate new vertical markets; risks from third-party products; failure to enroll individuals during the Medicare annual enrollment period; our ability to attract, integrate and retain qualified personnel; our dependence on lead providers and ability to compete for leads; failure to obtain and/or convert sales leads to actual sales of insurance policies; access to data from consumers and insurance carriers; accuracy of information provided from and to consumers during the insurance shopping process; cost-effective advertisement through internet search engines; ability to contact consumers and market products by telephone; global economic conditions, including inflation; disruption to operations as a result of future acquisitions; significant estimates and assumptions in the preparation of our financial statements; impairment of goodwill; our ability to regain and maintain compliance with NYSE listing standards; potential litigation and other legal proceedings or inquiries; our existing and future indebtedness; our ability to maintain compliance with our debt covenants; access to additional capital; failure to protect our intellectual property and our brand; fluctuations in our financial results caused by seasonality; accuracy and timeliness of commissions reports from insurance carriers; timing of insurance carriers' approval and payment practices; factors that impact our estimate of the constrained lifetime value of commissions per policyholder; changes in accounting rules, tax legislation and other legislation; disruptions or failures of our technological infrastructure and platform; failure to maintain relationships with third-party service providers; cybersecurity breaches or other attacks involving our systems or those of our insurance carrier partners or third-party service providers; our ability to protect consumer information and other data; failure to market and sell Medicare plans effectively or in compliance with laws; and other factors related to our pharmacy business, including manufacturing or supply chain disruptions, access to and demand for prescription drugs, and regulatory changes or other industry developments that may affect our pharmacy operations. For a further discussion of these and other risk factors that could impact our future results and performance, see the section entitled "Risk Factors" in the most recent Annual Report on Form 10-K (the "Annual Report") and subsequent periodic reports filed by us with the Securities and Exchange Commission. Accordingly, you should not place undue reliance on any such forward-looking statements. Any forward-looking statement speaks only as of the date on which it is made, and, except as otherwise required by law, we do not undertake any obligation to publicly update or review any forward-looking statement, whether as a result of new information, future developments or otherwise.

About SelectQuote:

Founded in 1985, SelectQuote (NYSE:SLQT) provides solutions that help consumers protect their most valuable assets: their families, health, and property. The company pioneered the model of providing unbiased comparisons from multiple, highly-rated insurance companies allowing consumers to choose the policy and terms that best meet their unique needs. Two foundational pillars underpin SelectQuote's success: a strong force of highly-trained and skilled agents who provide a consultative needs analysis for every consumer, and proprietary technology that sources and routes high-quality leads.

With an ecosystem offering high touchpoints for consumers across Insurance, Medicare, Pharmacy, and Value-Based Care, the company now has four core business lines: SelectQuote Senior, SelectQuote Healthcare Services, SelectQuote Life, and SelectQuote Auto and Home. SelectQuote Senior serves the needs of a demographic that sees around 10,000 people turn 65 each day with a range of Medicare Advantage and Medicare Supplement plans. SelectQuote Healthcare Services is comprised of the SelectRx Pharmacy, a specialized medication management pharmacy, and Population Health which proactively connects its members with best-in-class healthcare services that fit each member's unique healthcare needs. The platform improves health outcomes and lowers healthcare costs through proactive engagement and access to high-value healthcare solutions.

Source: SelectQuote, Inc.

SELECTQUOTE, INC. AND SUBSIDIARIES CONSOLIDATED BALANCE SHEETS (Unaudited) (In thousands)
	September 30, 2024			June 30, 2024
ASSETS
CURRENT ASSETS:
Cash and cash equivalents	$	10,444		$	42,690
Accounts receivable, net of allowances of $10.1 million and $8.2 million, respectively		99,534			150,035
Commissions receivable-current		176,760			119,871
Other current assets		20,144			20,327
Total current assets		306,882			332,923
COMMISSIONS RECEIVABLE—Net		743,024			761,446
PROPERTY AND EQUIPMENT—Net		18,191			18,973
SOFTWARE—Net		14,224			13,978
OPERATING LEASE RIGHT-OF-USE ASSETS		22,591			23,437
INTANGIBLE ASSETS—Net		9,162			10,194
GOODWILL		29,438			29,438
OTHER ASSETS		3,359			3,519
TOTAL ASSETS	$	1,146,871		$	1,193,908

LIABILITIES AND SHAREHOLDERS' EQUITY
CURRENT LIABILITIES:
Accounts payable	$	51,108		$	36,587
Accrued expenses		15,409			16,904
Accrued compensation and benefits		44,735			57,594
Operating lease liabilities—current		4,764			4,709
Current portion of long-term debt		43,290			45,854
Contract liabilities		2,952			8,066
Other current liabilities		4,487			4,873
Total current liabilities		166,745			174,587
LONG-TERM DEBT, NET—less current portion		637,155			637,480
DEFERRED INCOME TAXES		46,018			37,478
OPERATING LEASE LIABILITIES		24,560			25,685
OTHER LIABILITIES		2,954			1,877
Total liabilities		877,432			877,107

COMMITMENTS AND CONTINGENCIES

SHAREHOLDERS' EQUITY:
Common stock, $0.01 par value		1,715			1,694
Additional paid-in capital		580,712			580,764
Accumulated deficit		(314,315	)		(269,769	)
Accumulated other comprehensive income		1,327			4,112
Total shareholders' equity		269,439			316,801
TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY	$	1,146,871		$	1,193,908

SELECTQUOTE, INC. AND SUBSIDIARIES CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS (Unaudited) (In thousands)
	Three Months Ended September 30,
		2024			2023
REVENUE:
Commissions and other services	$	139,380		$	137,942
Pharmacy		152,883			94,788
Total revenue		292,263			232,730

OPERATING COSTS AND EXPENSES:
Cost of commissions and other services revenue		65,733			72,511
Cost of goods sold—pharmacy revenue		129,524			84,008
Marketing and advertising		63,764			62,323
Selling, general, and administrative		36,145			28,666
Technical development		9,074			7,637
Total operating costs and expenses		304,240			255,145

LOSS FROM OPERATIONS		(11,977	)		(22,415	)

INTEREST EXPENSE, NET		(23,031	)		(21,397	)
OTHER EXPENSE, NET		(12	)		(38	)
LOSS BEFORE INCOME TAX EXPENSE (BENEFIT)		(35,020	)		(43,850	)
INCOME TAX EXPENSE (BENEFIT)		9,526			(12,799	)

NET LOSS	$	(44,546	)	$	(31,051	)

NET LOSS PER SHARE:
Basic	$	(0.26	)	$	(0.19	)
Diluted	$	(0.26	)	$	(0.19	)

WEIGHTED-AVERAGE COMMON STOCK OUTSTANDING USED IN PER SHARE AMOUNTS:
Basic		170,431			167,453
Diluted		170,431			167,453

OTHER COMPREHENSIVE LOSS NET OF TAX:
Change in cash flow hedge		(2,785	)		(2,010	)
OTHER COMPREHENSIVE LOSS		(2,785	)		(2,010	)
COMPREHENSIVE LOSS	$	(47,331	)	$	(33,061	)

SELECTQUOTE, INC. AND SUBSIDIARIES CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) (In thousands)
	Three Months Ended September 30,
		2024			2023
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	$	(44,546	)	$	(31,051	)
Adjustments to reconcile net loss to net cash and cash equivalents used in operating activities:					—
Depreciation and amortization		5,599			5,989
Loss on disposal of property, equipment, and software		68			9
Share-based compensation expense		3,846			3,175
Deferred income taxes		9,526			(13,049	)
Amortization of debt issuance costs and debt discount		1,064			1,612
Accrued interest payable in kind		5,289			3,622
Non-cash lease expense		903			784
Changes in operating assets and liabilities:
Accounts receivable, net		50,501			38,693
Commissions receivable		(38,466	)		(29,148	)
Other assets		(3,516	)		(2,027	)
Accounts payable and accrued expenses		12,761			5,257
Operating lease liabilities		(1,127	)		(1,498	)
Other liabilities		(18,512	)		(6,039	)
Net cash used in operating activities		(16,610	)		(23,671	)
CASH FLOWS FROM INVESTING ACTIVITIES:
Purchases of property and equipment		(442	)		(616	)
Proceeds from sales of property and equipment		—			253
Purchases of software and capitalized software development costs		(2,132	)		(1,782	)
Net cash used in investing activities		(2,574	)		(2,145	)
CASH FLOWS FROM FINANCING ACTIVITIES:
Payments on Term Loans		(8,471	)		(8,471	)
Payments on other debt		(30	)		(37	)
Proceeds from common stock options exercised and employee stock purchase plan		38			—
Payments of tax withholdings related to net share settlement of equity awards		(3,915	)		(346	)
Payments of debt issuance costs		(684	)		—
Net cash used in financing activities		(13,062	)		(8,854	)
NET DECREASE IN CASH AND CASH EQUIVALENTS		(32,246	)		(34,670	)
CASH AND CASH EQUIVALENTS—Beginning of period		42,690			83,156
CASH AND CASH EQUIVALENTS—End of period	$	10,444		$	48,486

SELECTQUOTE, INC. AND SUBSIDIARIES Adjusted EBITDA to Loss before income tax expense (benefit) Reconciliation (Unaudited)
	Three Months Ended September 30, 2024
(in thousands)	Senior		Healthcare Services		Life		Total
Adjusted Segment EBITDA	$	7,724	$	4,878	$	5,960	$	18,562
All other Adjusted EBITDA								3,797
Corporate & elimination of intersegment profits								(24,042	)
Adjusted EBITDA								(1,683	)

Share-based compensation expense								(3,846	)
Transaction costs ⁽¹⁾								(826	)
Depreciation and amortization								(5,599	)
Loss on disposal of property, equipment, and software, net								(35	)
Interest expense, net								(23,031	)
Loss before income tax expense (benefit)							$	(35,020	)

	Three Months Ended September 30, 2023
(in thousands)	Senior			Healthcare Services		Life		Total
Adjusted Segment EBITDA	$	(1,335	)	$	2,322	$	5,240	$	6,227
All other Adjusted EBITDA									3,319
Corporate & elimination of intersegment profits									(20,922	)
Adjusted EBITDA									(11,376	)

Share-based compensation expense									(3,175	)
Transaction costs (1)									(1,904	)
Depreciation and amortization									(5,989	)
Loss on disposal of property, equipment, and software									(9	)
Interest expense, net									(21,397	)
Loss before income tax expense (benefit)								$	(43,850	)

SELECTQUOTE, INC. AND SUBSIDIARIES Net Income (Loss) to Adjusted EBITDA Reconciliation (Unaudited)
Guidance Net income (loss) to Adjusted EBITDA reconciliation, year ending June 30, 2025:
(in thousands)	Range
Net income (loss)	$	(59,000	)	$	3,000
Income tax expense		13,000			1,000
Interest expense, net		100,000			90,000
Depreciation and amortization		24,000			20,000
Share-based compensation expense		16,000			13,000
Transaction costs		6,000			3,000
Adjusted EBITDA	$	100,000		$	130,000

View source version on businesswire.com: https://www.businesswire.com/news/home/20241104387638/en/

SelectQuote, Inc. Reports First Quarter of Fiscal Year 2025 Results